✦ LIBER ✦

861 Safety and Efficacy of Pf-00547,659, a Fully Human Anti-MAdCAM Antibody, in Ulcerative Colitis. Results of a First in Human Study

✍ Scribed by Severine Vermeire; Subrata Ghosh; Julian Panes; Jens Frederik Dahlerup; Andreas Luegering; Jana Sirotiakova; U. Strauch; G. Burgess; J. Spanton; W. Niezychowski

Book ID: 119430445
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 81 KB
Volume: 136
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(09)60590-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

W1042 Mechanistic Population Pharmacokin

W1042 Mechanistic Population Pharmacokinetics (PK) Model of PF-00547659, a Fully Human IgG2 Anti-MAdCAM Antibody, in Ulcerative Colitis Patients: Results of a First in Human (Fih) Study

✍ Martin, Steven W.; Magnusson, Matts O.; Matthews, Ivan T.; Burgess, Gary; Niezyc 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Efficacy and Safety of Canakinumab (ACZ8

Efficacy and Safety of Canakinumab (ACZ885), a Fully Human Anti-Interleukin-1b-Antibody, in Cryopyrin Associated Periodic Fever Syndrome Results of a Multicenter, Randomized, Double-blind, Phase III Study

✍ Lachman, H.; Kone-Paut, I.; Kuemmerle-Deschner, J.; Leslie, K.; Hachulla, E.; Qu 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Efficacy and safety results of secukinum

Efficacy and safety results of secukinumab, a fully human monoclonal anti-interleukin-17a antibody, in the treatment of moderate-to-severe plaque psoriasis: A phase II regimen-finding trial

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB

704 A Phase 1 Open-Label, Single-Dose, D

704 A Phase 1 Open-Label, Single-Dose, Dose-Escalation Study of Mdx-1100, a High-Affinity, Neutralizing, Fully Human Igg1κ Anti-CXCL10 (Ip10) Monoclonal Antibody, in Ulcerative Colitis

✍ Robert Hardi; Lloyd Mayer; Stephan R. Targan; Michael Yellin; Pina M. Cardarelli 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 185 KB

Efficacy and Safety of AMG 145, a Fully

Efficacy and Safety of AMG 145, a Fully Human Monoclonal Antibody to PCSK9: Data from Four Phase 2 Studies in Over 1200 Patients

✍ Raal, Frederick; Giugliano, Robert; Koren, Michael J.; Sullivan, David; Roth, El 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 43 KB

Efficacy and safety of the fully human a

Efficacy and safety of the fully human anti-tumour necrosis factor monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

✍ van de Putte, L B A 📂 Article 📅 2003 🏛 BMJ Publishing Group 🌐 English ⚖ 400 KB